Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 6, 2023; 11(22): 5296-5302
Published online Aug 6, 2023. doi: 10.12998/wjcc.v11.i22.5296
Zimberelimab plus chemotherapy as the first-line treatment of malignant peritoneal mesothelioma: A case report and review of literature
Xiao-Dong Peng, Zhen-Yu You, Lian-Xiang He, Qi Deng
Xiao-Dong Peng, Zhen-Yu You, Department of Cancer, The First Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi Province, China
Lian-Xiang He, Qi Deng, Department of Medical Affairs, Guangzhou Gloria Bioscience Co.,Ltd., Beijing 100005, China
Author contributions: Deng Q is responsible for writing the manuscript; He LX revised this manuscript; Peng XD and You ZY provided idea and case, and reviewed the manuscript; all authors have read and approve the final manuscript.
Informed consent statement: The patient provided a written informed consent form.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xiao-Dong Peng, MD, Chief Physician, Department of Cancer, The First Affiliated Hospital of Nanchang University, No. 1519 Dongyue Avenue, Nanchang 330006, Jiangxi Province, China. pxddhbb@163.com
Received: March 1, 2023
Peer-review started: March 1, 2023
First decision: May 25, 2023
Revised: June 21, 2023
Accepted: July 11, 2023
Article in press: July 11, 2023
Published online: August 6, 2023
Processing time: 155 Days and 3.8 Hours
Core Tip

Core Tip: Malignant peritoneal mesothelioma (MPeM) is a rare cancer with a poor prognosis at advanced stage. Here, we present the first case of a patient with epithelioid subtype MPeM, who was treatment-naïve and benefited from initial programmed cell death 1 inhibitor plus standard chemotherapy with a prolonged progression-free survival and good tolerance. We would like to share our experience with immunochemotherapy, which will help clinicians make appropriate decisions in the future.